Furthermore, irbesartan can ameliorate hyperlipidemia and liver steatosis by upregulating the expression of PPAR-γ, activating the AMP-activated protein kinase/protein kinase B/mTOR signaling pathway and inducing liver autophagy [56]. The gene discussed is PPARG; the disease is fatty liver disease.